Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychomotor Performance | 73 | 2012 | 504 | 6.390 |
Why?
|
| Analgesics, Opioid | 32 | 2014 | 539 | 4.210 |
Why?
|
| Oxycodone | 14 | 2013 | 35 | 4.170 |
Why?
|
| Nitrous Oxide | 28 | 2010 | 108 | 3.700 |
Why?
|
| Affect | 42 | 2011 | 409 | 2.950 |
Why?
|
| Morphine | 19 | 2014 | 127 | 2.330 |
Why?
|
| Narcotics | 12 | 2012 | 74 | 2.130 |
Why?
|
| Anesthetics, Inhalation | 13 | 2018 | 97 | 1.950 |
Why?
|
| Double-Blind Method | 64 | 2018 | 1778 | 1.900 |
Why?
|
| Cross-Over Studies | 45 | 2018 | 409 | 1.860 |
Why?
|
| Substance-Related Disorders | 18 | 2011 | 469 | 1.600 |
Why?
|
| Dose-Response Relationship, Drug | 42 | 2019 | 1946 | 1.280 |
Why?
|
| Cognition | 23 | 2011 | 670 | 1.280 |
Why?
|
| Ethanol | 11 | 2011 | 282 | 1.080 |
Why?
|
| Choice Behavior | 12 | 2008 | 163 | 1.060 |
Why?
|
| Pain | 10 | 2013 | 416 | 1.050 |
Why?
|
| Motivation | 8 | 2013 | 341 | 1.010 |
Why?
|
| Alcohol Drinking | 8 | 2009 | 301 | 1.000 |
Why?
|
| Methyl Ethers | 6 | 2008 | 33 | 0.970 |
Why?
|
| Adult | 104 | 2019 | 29498 | 0.940 |
Why?
|
| Arousal | 13 | 2005 | 175 | 0.910 |
Why?
|
| Smoking | 11 | 2013 | 673 | 0.850 |
Why?
|
| Opioid-Related Disorders | 9 | 2012 | 254 | 0.830 |
Why?
|
| Analgesics | 4 | 2013 | 131 | 0.830 |
Why?
|
| Male | 107 | 2019 | 46983 | 0.770 |
Why?
|
| Hydrocodone | 3 | 2008 | 8 | 0.750 |
Why?
|
| Carisoprodol | 2 | 2011 | 4 | 0.700 |
Why?
|
| Female | 98 | 2019 | 51441 | 0.690 |
Why?
|
| Analgesics, Non-Narcotic | 5 | 2008 | 53 | 0.690 |
Why?
|
| Psychomotor Disorders | 4 | 2008 | 20 | 0.660 |
Why?
|
| Sex Characteristics | 4 | 2010 | 350 | 0.630 |
Why?
|
| Pain Measurement | 10 | 2013 | 401 | 0.630 |
Why?
|
| Drug Interactions | 13 | 2012 | 239 | 0.610 |
Why?
|
| Humans | 126 | 2019 | 97913 | 0.590 |
Why?
|
| Cold Temperature | 8 | 2004 | 162 | 0.580 |
Why?
|
| Butorphanol | 4 | 2004 | 9 | 0.570 |
Why?
|
| Fentanyl | 9 | 1996 | 92 | 0.560 |
Why?
|
| Euphoria | 6 | 2010 | 47 | 0.560 |
Why?
|
| Memory | 7 | 2012 | 237 | 0.510 |
Why?
|
| Behavior | 5 | 1999 | 86 | 0.500 |
Why?
|
| Emotions | 4 | 2011 | 387 | 0.460 |
Why?
|
| Nausea | 2 | 2013 | 94 | 0.450 |
Why?
|
| Sex Factors | 5 | 2019 | 1138 | 0.450 |
Why?
|
| Muscle Relaxants, Central | 2 | 2011 | 11 | 0.430 |
Why?
|
| Propofol | 6 | 1996 | 95 | 0.430 |
Why?
|
| Isoflurane | 4 | 2018 | 58 | 0.410 |
Why?
|
| Immersion | 4 | 2004 | 23 | 0.400 |
Why?
|
| Hydromorphone | 3 | 2011 | 11 | 0.400 |
Why?
|
| Hemodynamics | 10 | 2008 | 746 | 0.400 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 153 | 0.400 |
Why?
|
| Prescription Drug Misuse | 1 | 2013 | 14 | 0.400 |
Why?
|
| Marijuana Smoking | 5 | 1992 | 32 | 0.390 |
Why?
|
| Analysis of Variance | 10 | 2009 | 889 | 0.390 |
Why?
|
| Naltrexone | 1 | 2014 | 140 | 0.380 |
Why?
|
| Injections, Intravenous | 14 | 2001 | 212 | 0.380 |
Why?
|
| Anticonvulsants | 2 | 2011 | 131 | 0.370 |
Why?
|
| GABA Modulators | 1 | 2012 | 8 | 0.360 |
Why?
|
| Alprazolam | 1 | 2012 | 4 | 0.360 |
Why?
|
| Pupil | 5 | 2014 | 21 | 0.350 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2011 | 40 | 0.340 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2011 | 85 | 0.340 |
Why?
|
| Young Adult | 10 | 2014 | 7490 | 0.340 |
Why?
|
| Administration, Inhalation | 10 | 2008 | 206 | 0.330 |
Why?
|
| Food Deprivation | 4 | 1992 | 23 | 0.320 |
Why?
|
| Surveys and Questionnaires | 14 | 2011 | 3014 | 0.320 |
Why?
|
| Analgesia | 3 | 1999 | 65 | 0.320 |
Why?
|
| Receptors, Opioid, mu | 4 | 2014 | 50 | 0.320 |
Why?
|
| Midazolam | 6 | 1996 | 48 | 0.310 |
Why?
|
| Pain Threshold | 4 | 1998 | 64 | 0.310 |
Why?
|
| Blood Pressure | 7 | 2005 | 910 | 0.310 |
Why?
|
| Mental Recall | 5 | 2007 | 173 | 0.290 |
Why?
|
| Acetaminophen | 2 | 2008 | 63 | 0.290 |
Why?
|
| Reaction Time | 7 | 2012 | 325 | 0.290 |
Why?
|
| Dextroamphetamine | 4 | 1992 | 108 | 0.290 |
Why?
|
| Codeine | 3 | 2005 | 12 | 0.280 |
Why?
|
| Reference Values | 8 | 2009 | 612 | 0.280 |
Why?
|
| Alcoholic Intoxication | 1 | 2008 | 39 | 0.270 |
Why?
|
| Anxiety | 1 | 2011 | 370 | 0.270 |
Why?
|
| Drug Combinations | 4 | 2011 | 201 | 0.270 |
Why?
|
| Caffeine | 3 | 2018 | 87 | 0.260 |
Why?
|
| Naloxone | 2 | 1999 | 80 | 0.250 |
Why?
|
| Anesthetics, Intravenous | 2 | 1997 | 44 | 0.250 |
Why?
|
| Central Nervous System Depressants | 2 | 1997 | 45 | 0.250 |
Why?
|
| Meperidine | 2 | 1999 | 11 | 0.250 |
Why?
|
| Fasting | 3 | 1992 | 166 | 0.240 |
Why?
|
| Narcotic Antagonists | 3 | 2014 | 181 | 0.240 |
Why?
|
| Automobile Driver Examination | 1 | 2006 | 1 | 0.240 |
Why?
|
| Impulsive Behavior | 1 | 2009 | 295 | 0.230 |
Why?
|
| Drug Prescriptions | 2 | 2008 | 157 | 0.230 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 91 | 0.230 |
Why?
|
| Motor Skills | 1 | 2006 | 79 | 0.230 |
Why?
|
| Automobile Driving | 1 | 2006 | 36 | 0.230 |
Why?
|
| Histamine H2 Antagonists | 1 | 2005 | 12 | 0.230 |
Why?
|
| Tramadol | 1 | 2005 | 14 | 0.230 |
Why?
|
| Carbon Monoxide | 8 | 1992 | 98 | 0.220 |
Why?
|
| Proton Pump Inhibitors | 1 | 2005 | 34 | 0.220 |
Why?
|
| Administration, Oral | 6 | 2011 | 674 | 0.220 |
Why?
|
| Cognition Disorders | 2 | 2005 | 240 | 0.220 |
Why?
|
| Substance Abuse Detection | 3 | 2013 | 13 | 0.210 |
Why?
|
| Valerian | 1 | 2004 | 3 | 0.210 |
Why?
|
| Plant Preparations | 1 | 2004 | 20 | 0.210 |
Why?
|
| Dextropropoxyphene | 1 | 2004 | 2 | 0.210 |
Why?
|
| Lorazepam | 4 | 2005 | 12 | 0.210 |
Why?
|
| Anesthetics | 3 | 1999 | 51 | 0.200 |
Why?
|
| Alcoholism | 2 | 1999 | 197 | 0.200 |
Why?
|
| Drug and Narcotic Control | 1 | 2003 | 8 | 0.190 |
Why?
|
| Gastroesophageal Reflux | 1 | 2005 | 129 | 0.190 |
Why?
|
| Respiration | 7 | 1999 | 275 | 0.190 |
Why?
|
| Anesthesia Recovery Period | 3 | 2018 | 56 | 0.190 |
Why?
|
| Marijuana Abuse | 2 | 1994 | 32 | 0.190 |
Why?
|
| Tropanes | 1 | 2002 | 2 | 0.190 |
Why?
|
| Heart Rate | 6 | 2014 | 535 | 0.190 |
Why?
|
| Nicotine | 5 | 1993 | 218 | 0.180 |
Why?
|
| Preanesthetic Medication | 1 | 2002 | 5 | 0.180 |
Why?
|
| Dental Anxiety | 1 | 2002 | 2 | 0.180 |
Why?
|
| Anesthesia, Dental | 1 | 2002 | 4 | 0.180 |
Why?
|
| Risk Factors | 9 | 2013 | 6220 | 0.170 |
Why?
|
| Placebos | 4 | 2011 | 209 | 0.170 |
Why?
|
| Time Factors | 11 | 2018 | 5566 | 0.170 |
Why?
|
| Anesthesiology | 3 | 1999 | 171 | 0.170 |
Why?
|
| Thiopental | 2 | 1997 | 16 | 0.160 |
Why?
|
| Infusions, Intravenous | 3 | 2014 | 412 | 0.150 |
Why?
|
| Anesthetics, Combined | 1 | 1999 | 4 | 0.150 |
Why?
|
| Alfentanil | 1 | 1999 | 2 | 0.150 |
Why?
|
| Azepines | 1 | 2019 | 29 | 0.150 |
Why?
|
| Drug Tolerance | 3 | 1996 | 59 | 0.150 |
Why?
|
| Prospective Studies | 9 | 2013 | 4815 | 0.150 |
Why?
|
| Research Design | 2 | 2013 | 658 | 0.140 |
Why?
|
| Pentazocine | 1 | 1998 | 2 | 0.140 |
Why?
|
| Citrates | 1 | 2018 | 28 | 0.140 |
Why?
|
| Anesthesia | 2 | 1999 | 174 | 0.140 |
Why?
|
| Attention | 5 | 2007 | 427 | 0.140 |
Why?
|
| Psychotropic Drugs | 1 | 1999 | 82 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 2 | 1996 | 142 | 0.140 |
Why?
|
| Ethers | 1 | 1997 | 13 | 0.130 |
Why?
|
| Verapamil | 2 | 1997 | 32 | 0.130 |
Why?
|
| Adjuvants, Anesthesia | 1 | 1997 | 4 | 0.130 |
Why?
|
| Piperidines | 1 | 1999 | 172 | 0.130 |
Why?
|
| Risk | 2 | 2013 | 660 | 0.130 |
Why?
|
| Neuropsychological Tests | 4 | 2012 | 568 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2013 | 1002 | 0.130 |
Why?
|
| Individuality | 3 | 2008 | 119 | 0.130 |
Why?
|
| Nalbuphine | 1 | 1997 | 3 | 0.130 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 118 | 0.130 |
Why?
|
| Accidents, Occupational | 1 | 1996 | 8 | 0.130 |
Why?
|
| Buprenorphine | 1 | 1997 | 57 | 0.120 |
Why?
|
| Anti-Anxiety Agents | 1 | 1996 | 23 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2019 | 351 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2019 | 411 | 0.120 |
Why?
|
| Methadone | 1 | 1996 | 54 | 0.120 |
Why?
|
| Self Administration | 3 | 2008 | 78 | 0.120 |
Why?
|
| Dronabinol | 3 | 1992 | 60 | 0.120 |
Why?
|
| Flumazenil | 1 | 1995 | 8 | 0.110 |
Why?
|
| Central Nervous System Stimulants | 1 | 2018 | 244 | 0.110 |
Why?
|
| Accidents, Traffic | 1 | 1996 | 108 | 0.110 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2015 | 4 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1108 | 0.110 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1995 | 55 | 0.110 |
Why?
|
| Miosis | 3 | 2004 | 10 | 0.110 |
Why?
|
| Anilides | 1 | 2015 | 50 | 0.110 |
Why?
|
| Breath Tests | 4 | 2001 | 59 | 0.110 |
Why?
|
| Respiratory Mechanics | 2 | 2008 | 109 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1996 | 255 | 0.100 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2014 | 82 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2019 | 9689 | 0.100 |
Why?
|
| Nifedipine | 1 | 1993 | 24 | 0.100 |
Why?
|
| Population | 1 | 2013 | 36 | 0.100 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 139 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 1995 | 255 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2013 | 66 | 0.100 |
Why?
|
| Anesthesia, Intravenous | 1 | 1993 | 36 | 0.100 |
Why?
|
| Hair | 1 | 1993 | 56 | 0.100 |
Why?
|
| Social Environment | 2 | 1992 | 199 | 0.100 |
Why?
|
| Ondansetron | 1 | 1993 | 8 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 169 | 0.100 |
Why?
|
| Pyridines | 1 | 2015 | 316 | 0.100 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1993 | 26 | 0.090 |
Why?
|
| Cycloparaffins | 1 | 1992 | 5 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2019 | 10922 | 0.090 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1993 | 76 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2013 | 224 | 0.090 |
Why?
|
| Toxicity Tests, Acute | 1 | 2011 | 3 | 0.090 |
Why?
|
| Pregabalin | 1 | 2011 | 7 | 0.090 |
Why?
|
| Thinking | 1 | 2012 | 40 | 0.090 |
Why?
|
| Respiratory Rate | 1 | 2011 | 27 | 0.090 |
Why?
|
| Neurology | 1 | 2012 | 85 | 0.090 |
Why?
|
| Social Isolation | 1 | 1992 | 73 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2012 | 120 | 0.080 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 2 | 1990 | 5 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 839 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 661 | 0.080 |
Why?
|
| Leukemia, Myeloid | 1 | 2011 | 241 | 0.080 |
Why?
|
| Plants, Toxic | 2 | 1987 | 23 | 0.080 |
Why?
|
| Amphetamines | 1 | 1990 | 18 | 0.080 |
Why?
|
| Psychopharmacology | 1 | 2009 | 26 | 0.080 |
Why?
|
| Pentobarbital | 1 | 1989 | 16 | 0.080 |
Why?
|
| Procaine | 1 | 1989 | 10 | 0.080 |
Why?
|
| Social Values | 1 | 2009 | 44 | 0.070 |
Why?
|
| Cannabis | 1 | 1990 | 41 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2009 | 89 | 0.070 |
Why?
|
| Lidocaine | 1 | 1989 | 62 | 0.070 |
Why?
|
| Conditioning, Operant | 4 | 2008 | 68 | 0.070 |
Why?
|
| Cotinine | 3 | 1997 | 15 | 0.070 |
Why?
|
| Methamphetamine | 1 | 1990 | 109 | 0.070 |
Why?
|
| Cocaine | 1 | 1989 | 84 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2008 | 109 | 0.070 |
Why?
|
| Norepinephrine | 3 | 2005 | 167 | 0.070 |
Why?
|
| Placebo Effect | 1 | 2008 | 37 | 0.070 |
Why?
|
| Drug Design | 1 | 2008 | 135 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1130 | 0.060 |
Why?
|
| Health Surveys | 1 | 2008 | 254 | 0.060 |
Why?
|
| Reward | 1 | 2009 | 224 | 0.060 |
Why?
|
| Smoke | 1 | 1986 | 29 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 109 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1995 | 0.060 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 20 | 0.060 |
Why?
|
| Neoplasms | 2 | 2019 | 3325 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 219 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 764 | 0.060 |
Why?
|
| Ambulatory Surgical Procedures | 3 | 1995 | 82 | 0.060 |
Why?
|
| Middle Aged | 8 | 2019 | 29366 | 0.060 |
Why?
|
| Self Concept | 1 | 2005 | 139 | 0.050 |
Why?
|
| Water | 2 | 1997 | 310 | 0.050 |
Why?
|
| Heroin Dependence | 2 | 2011 | 16 | 0.050 |
Why?
|
| Forearm | 1 | 2004 | 33 | 0.050 |
Why?
|
| Serotonin | 1 | 2005 | 211 | 0.050 |
Why?
|
| Drug Synergism | 2 | 1998 | 317 | 0.050 |
Why?
|
| Prevalence | 1 | 2008 | 1381 | 0.050 |
Why?
|
| Oxygen | 3 | 1999 | 796 | 0.050 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2004 | 28 | 0.050 |
Why?
|
| Reinforcement Schedule | 3 | 2008 | 16 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2004 | 252 | 0.050 |
Why?
|
| Volunteers | 1 | 2001 | 21 | 0.040 |
Why?
|
| Random Allocation | 2 | 1993 | 312 | 0.040 |
Why?
|
| Amitriptyline | 1 | 2001 | 11 | 0.040 |
Why?
|
| Adolescent | 5 | 1993 | 10078 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2002 | 230 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2001 | 118 | 0.040 |
Why?
|
| Gait | 1 | 2001 | 88 | 0.040 |
Why?
|
| Sleep | 2 | 1996 | 469 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 1999 | 35 | 0.040 |
Why?
|
| Sensation | 1 | 1999 | 49 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2019 | 61 | 0.040 |
Why?
|
| Indazoles | 1 | 2019 | 63 | 0.040 |
Why?
|
| Drug Utilization | 1 | 1999 | 65 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 264 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2019 | 2582 | 0.030 |
Why?
|
| Incidence | 1 | 2003 | 1774 | 0.030 |
Why?
|
| Attitude | 1 | 1999 | 133 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2001 | 511 | 0.030 |
Why?
|
| Diltiazem | 1 | 1997 | 6 | 0.030 |
Why?
|
| Nimodipine | 1 | 1997 | 12 | 0.030 |
Why?
|
| Mental Competency | 1 | 1997 | 49 | 0.030 |
Why?
|
| Aged | 4 | 2019 | 21703 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 581 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 2033 | 0.030 |
Why?
|
| Infusion Pumps | 1 | 1996 | 26 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 902 | 0.030 |
Why?
|
| Motor Activity | 1 | 1999 | 331 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1192 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 234 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 1999 | 399 | 0.030 |
Why?
|
| Recurrence | 1 | 1999 | 1251 | 0.030 |
Why?
|
| Columbidae | 4 | 1990 | 4 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 1996 | 34 | 0.030 |
Why?
|
| Long-Term Care | 1 | 1996 | 66 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 1996 | 141 | 0.030 |
Why?
|
| Coffee | 1 | 1995 | 10 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1527 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1996 | 162 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 1996 | 128 | 0.030 |
Why?
|
| United States | 2 | 2012 | 8155 | 0.030 |
Why?
|
| Informed Consent | 1 | 1997 | 281 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1998 | 983 | 0.030 |
Why?
|
| Pressure | 1 | 1995 | 173 | 0.030 |
Why?
|
| Personality Inventory | 1 | 1994 | 112 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1967 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 4020 | 0.030 |
Why?
|
| Reflex, Pupillary | 1 | 1994 | 7 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 168 | 0.030 |
Why?
|
| Temperature | 1 | 1995 | 443 | 0.030 |
Why?
|
| Sufentanil | 1 | 1993 | 3 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 2076 | 0.020 |
Why?
|
| Smell | 1 | 1994 | 123 | 0.020 |
Why?
|
| Generalization, Stimulus | 2 | 1990 | 3 | 0.020 |
Why?
|
| Pulse | 1 | 1992 | 14 | 0.020 |
Why?
|
| Models, Biological | 1 | 1999 | 1809 | 0.020 |
Why?
|
| Internationality | 1 | 2012 | 79 | 0.020 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1992 | 16 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 3207 | 0.020 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 1990 | 80 | 0.020 |
Why?
|
| Hunger | 1 | 1992 | 22 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 1992 | 33 | 0.020 |
Why?
|
| Personality Assessment | 1 | 1992 | 99 | 0.020 |
Why?
|
| Animals | 6 | 1999 | 28864 | 0.020 |
Why?
|
| Energy Intake | 1 | 1992 | 99 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2011 | 77 | 0.020 |
Why?
|
| Ketone Bodies | 1 | 1991 | 16 | 0.020 |
Why?
|
| Memory, Short-Term | 3 | 2005 | 256 | 0.020 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1992 | 112 | 0.020 |
Why?
|
| Dopamine | 2 | 1983 | 279 | 0.020 |
Why?
|
| Hormones | 1 | 2011 | 138 | 0.020 |
Why?
|
| Cytarabine | 1 | 2011 | 218 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1992 | 202 | 0.020 |
Why?
|
| Fenfluramine | 1 | 1990 | 21 | 0.020 |
Why?
|
| Drinking Behavior | 1 | 1990 | 13 | 0.020 |
Why?
|
| Glycosuria | 1 | 1989 | 4 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 300 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1990 | 93 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 1993 | 306 | 0.020 |
Why?
|
| Amphetamine | 1 | 1990 | 105 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 45 | 0.020 |
Why?
|
| Filtration | 1 | 1986 | 26 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2010 | 1086 | 0.010 |
Why?
|
| Volatilization | 1 | 2005 | 6 | 0.010 |
Why?
|
| Time Perception | 1 | 2005 | 23 | 0.010 |
Why?
|
| Verbal Learning | 1 | 2005 | 31 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1989 | 913 | 0.010 |
Why?
|
| Discrimination Learning | 1 | 2005 | 63 | 0.010 |
Why?
|
| Problem Solving | 1 | 2005 | 59 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 4071 | 0.010 |
Why?
|
| Stereotyped Behavior | 1 | 1983 | 14 | 0.010 |
Why?
|
| Telencephalon | 1 | 1982 | 31 | 0.010 |
Why?
|
| Desipramine | 1 | 2001 | 9 | 0.010 |
Why?
|
| Paroxetine | 1 | 2001 | 26 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2440 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 2371 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 238 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 1403 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1983 | 383 | 0.010 |
Why?
|
| Droperidol | 1 | 1995 | 3 | 0.010 |
Why?
|
| Ketamine | 1 | 1995 | 30 | 0.010 |
Why?
|
| Reference Standards | 1 | 1995 | 146 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1991 | 322 | 0.000 |
Why?
|
| Learning | 1 | 1993 | 308 | 0.000 |
Why?
|
| Apomorphine | 1 | 1983 | 8 | 0.000 |
Why?
|
| Haloperidol | 1 | 1983 | 29 | 0.000 |
Why?
|
| Pons | 1 | 1982 | 25 | 0.000 |
Why?
|
| Substantia Nigra | 1 | 1982 | 28 | 0.000 |
Why?
|
| Brain Chemistry | 1 | 1983 | 110 | 0.000 |
Why?
|
| Basal Ganglia | 1 | 1982 | 47 | 0.000 |
Why?
|
| Olfactory Bulb | 1 | 1982 | 41 | 0.000 |
Why?
|
| Corpus Striatum | 1 | 1982 | 83 | 0.000 |
Why?
|
| Eating | 1 | 1983 | 164 | 0.000 |
Why?
|
| Neural Pathways | 1 | 1982 | 329 | 0.000 |
Why?
|